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Purpose: Nonadherence to indicated therapy reduces treatment effectiveness and may
increase cost of care. HUMIRA Complete, a Patient Support Program (PSP), aims to reduce
nonadherence in patients prescribed adalimumab (ADA). The objective of this study was to
assess the relationship between participation in the PSP and prescription abandonment rates
among ADA-treated patients.
Patients and methods: This longitudinal study using patient-level data from AbbVie’s
PSP linked with medical and pharmacy claims data included patients ≥18 years with an
ADA-approved indication, ≥1 pharmacy claim for ADA, and available data ≥3 months
before and ≥6 months after the index date (deﬁned as the initial ADA claim [01/2015 to
02/2017]). Abandonment was deﬁned as reversal of initial ADA prescription with no paid
claim during 3-month follow-up. Abandonment rates were compared between PSP and nonPSP cohorts using multivariable logistic regression controlling for potentially confounding
baseline characteristics.
Results: In 17,371 patients (9,851 PSP; 7,520 non-PSP), the overall abandonment rate
was 10.8–16.8% across indications. The odds of ADA abandonment were 70% less for
PSP vs non-PSP patients (5.6% vs 20.4%, odds ratio [OR]=0.30, [95% conﬁdence
interval (CI)=0.27–0.33] P<0.001), 38% less for patients using specialty vs retail
pharmacy (OR=0.62, 95% CI=0.56–0.69, P<0.001), 20% less for those with income of
$50–99K vs $0–49K (OR=0.80, 95% CI=0.69–0.92, P<0.01), and 78% greater for those
with copayment of $26–100 vs $0–25 (OR=1.78, 95% CI=1.55–2.05, P<0.001).
Conclusion: Participation in the PSP, higher income, and using a specialty pharmacy were
associated with lower odds of abandoning ADA therapy, whereas increased copayments were
associated with greater abandonment. PSPs should be considered to improve initiation of ADA
therapy.
Keywords: adherence, drug utilization, managed care, outcomes research/analysis, patient
education, personnel management

Introduction
As health care costs continue to increase, efforts are being made to provide patientcentered care that is responsive to patients’ needs and preferences while managing
costs.1 This is particularly true for patients with chronic diseases that require longterm medical management. Rheumatic diseases can be difﬁcult to diagnose and
early referral to a rheumatologist can shorten time to diagnosis and provide quicker
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access to appropriate treatment.2 For patients with
immune-mediated inﬂammatory diseases, the availability
of biologic therapies has had a signiﬁcant positive impact
including attainment of clinical remission,3–9 reduced risk
of extra-articular complications,10 and improved healthrelated quality of life.11–17 However, to effectively treat
these diseases, patients not only need to have access to
therapy, but they also need to adhere to a speciﬁc treatment
regimen. Non-adherence rates for biologic therapies
among patients with inﬂammatory bowel disease and rheumatoid arthritis are estimated to be 25–34%.18–20 Among
patients with inﬂammatory bowel disease, nonadherence
to therapy is associated with a greater rate of hospitalization, higher medical costs, and increased disability.21–23
One component of nonadherence is failure to initiate
therapy after a prescription has been written.24,25 Several
studies have shown that 17–28% of patients do not obtain
new prescriptions from the pharmacy despite a written
prescription from their physician,26–29 and 39% of patients
with rheumatoid arthritis do not ﬁll new prescriptions for
injectable biologic disease-modifying antirheumatic
drugs.25 Patients may abandon their ﬁrst prescription for
several reasons including concerns about costs, decisions
regarding self-administration versus outpatient injection or
infusion of medication, fear of needles, extent of patient/
physician communication, lack of education about the
beneﬁts and side effects of the medication, and/or concerns
about administering a complex medication regimen to
manage their medical condition.25–27
In an attempt to improve outcomes, patient support
programs (PSPs) have been developed to assist patients
with chronic diseases and provide them with the knowledge and support to actively participate in the management
of their own care.30–34 In the US, AbbVie offers a PSP to
all patients treated with adalimumab (ADA) designed to
provide one-to-one, personalized support to increase medication adherence by behavior modiﬁcation. Since the
launch, more than 300,000 patients with prescriptions for
ADA have opted-in to the PSP. In 2015, the Nurse
Ambassador component was added to the PSP and the
program, called HUMIRA Complete,35 was launched at
the national level in the US to provide educational
resources and support to empower patients to actively
manage their treatment and understand various aspects of
their chronic disease. The team of Nurse Ambassadors
includes more than 400 registered nurses who provide
unique, high-touch, coordinated care for ADA-treated
patients. Individuals who opt-in to the Nurse Ambassador
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component of the PSP are assigned to a dedicated
Ambassador, a trained nurse who does not provide medical
advice, but provides personalized one-on-one educational
support to ensure that patients can access treatment-related
educational resources and understand the importance of
following their ADA treatment plan as prescribed by
their physician. The Nurse Ambassador quickly reaches
out to these patients to motivate and educate them, so they
understand how to initiate the prescribed treatment plan
and navigate the insurance and ﬁnancial assistance processes. The Nurse Ambassador program supplements other
components of the PSP, such as injection training and
medication reminders in an effort to empower patients to
adhere to their prescribed treatment plan.
The 2015 nationwide availability of AbbVie’s PSP
offers a unique opportunity to study the effectiveness of
the patient-centered care offered by the PSP on abandonment of ADA treatment initiation across all ADAapproved indications. This is accomplished by providing
a means to collect relevant patient-level data in the PSP
and linking the collected data to pertinent outcomes. The
objective of this study was to assess the association
between participation in the PSP and the rate of ADA
treatment abandonment across autoimmune diseases
including inﬂammatory bowel disease (Crohn’s disease
or ulcerative colitis), rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, and uveitis. The relationship between PSP participation and continuation of ADA treatment after initiation
was also examined.

Methods
Data source
A longitudinal, retrospective cohort study was conducted
using patient-level data obtained by linking AbbVie’s PSP
database (AbbVie Inc., North Chicago, IL, USA) with the
Symphony Health Solutions (SHS, Horsham PA, USA)
administrative claims database. The PSP database contains
the dates that patients opted-in to each component (assistance with medication cost and insurance questions, face-toface interactions with an Ambassador, a nurse-led injection
training program [to supplement the initial injection training
provided by the physician], resources to familiarize patients
with the self-injection process, instructions on the disposal
of used pens and syringes, reminders to take medication as
prescribed, and an insulated bag to keep ADA at the
required temperature when traveling short distances) of
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the AbbVie PSP that can be used to identify the ﬁrst PSP
opt-in date for each patient.
The SHS administrative claims database contains longitudinal, patient-level information on medical and pharmacy claims from a geographically diverse large set of
electronic claims processors across the United States and
includes International Classiﬁcation of Diseases, Ninth
and Tenth Revisions (ICD-9/10) codes, service dates,
charge amounts, procedure codes, National Drug Codes,
and pharmacy types. Pharmacy data contain a claim status
code that distinguishes paid, rejected, or reversed claims.
A reversed claim indicates a claim was approved by the
payer, but the prescription was not picked up at the pharmacy by the patient.
Each data provider with SHS used a proprietary deidentiﬁcation engine to create a series of unique patient
tokens that replace personally identiﬁable data. These
tokens or artiﬁcial identiﬁers were then used to link the
claims data from SHS to the PSP data. The de-identiﬁcation engine (SynomaTM) is a Health Insurance Portability
and Accountability Act of 1996 (HIPAA) compliant industry standard encryption engine supplied by SHS and is
designed to protect the anonymity of the data. An external
HIPAA statistician evaluated the risk associated with
linked data content and certiﬁed that the resulting ﬁles
ensured patient anonymity. Because these data were completely de-identiﬁed before providing the dataset to the
researchers for analysis, institutional review board
approval of this study was deemed not necessary.

Selection of patients
Patients ≥18 years of age with a ﬁrst ADA prescription
claim (paid or reversed) from January 2015 to February
2017 were selected for the analysis (Figure 1). Patients
whose initial ADA claim was reimbursed by the government (Medicare or Medicaid) were also excluded because
receipt of copayment cards is prohibited for Medicare/
Medicaid patients; therefore, these patients were not able
to utilize all components of the PSP. The index date was
deﬁned as the initial ADA claim. Patients with an ADA
claim prior to 2015 were excluded from the study because
the Nurse Ambassador component was not added to the
PSP until 2015. Patients were required to have a diagnosis
for an autoimmune disease of interest (inﬂammatory bowel
disease [Crohn’s disease or ulcerative colitis], rheumatoid
arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis,
hidradenitis suppurativa, or uveitis) prior to the index date
based on the ICD-9/10 codes listed in Table S1. Assignment
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to an indication cohort was based on a diagnosis for that
indication and no subsequent diagnosis for another autoimmune disease before the index ADA claim (eg, patients
with a diagnosis for rheumatoid arthritis had no subsequent
diagnosis for any other autoimmune disease before the
initial ADA claim). Patients had to have at least 1 medical
claim in the 3 months prior to the index date to assess
baseline characteristics and have pharmacy data coverage
for ≥3 months before and ≥6 months after the index date to
observe treatment and abandonment history. The SHS data
do not contain an enrollment or eligibility ﬁle, so data
coverage was determined as an observed claim before and
after the study period.36
The PSP cohort included patients who opted-in to the
PSP within 30 days pre- and post-index date and participated in the Ambassador program with an initial call and
at least one follow-up with the nurse. Opting-in to the PSP
was assessed after the initial claim to allow for delays in
registration and include patients who opted-in to the PSP
after realizing the expected copayment amount. The nonPSP cohort included patients who did not opt-in to any
PSP component during the 30 days before or after the
index date. Patients who opted-in to the PSP within 30
days of their index date but did not participate in the
Ambassador program were excluded.

Outcomes
The primary outcome measure was prescription abandonment assessed as reversal of the initial ADA claim (ie,
patient did not take possession of the medication) with no
paid ADA claim (pharmacy or medical) in the following
3-month period after the index date.37,38 The secondary
outcome measure was occurrence of a second ADA prescription ﬁll after ADA initiation in the 6 months following the initial ADA claim.

Data analysis
Baseline characteristics were assessed during the 3 months
before the index date. Cohorts were compared using
Wilcoxon rank-sum tests and chi-square tests for continuous and categorical variables, respectively. Abandonment
rate was calculated as the number of patients who abandoned ADA initiation divided by the total number of
patients with a paid or reversed initial claim; comparisons
between cohorts were based on two-sample z-tests of
proportions.
The odds of abandoning ADA treatment were assessed
using a multivariable logistic regression with abandonment
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≥1 pharmacy claim for biologic or immunomodulator (1/1/2015 – 2/28/2017)a
N=557,259

≥1 pharmacy claim for ADA (paid or reversed), earliest ADA claim was index date
N=244,560

Earliest ADA claim not covered by Medicare or Medicaidb
N=159,732

≥1 medical claim in the 3 months before the index date
N=83,008

Pharmacy coverage for ≥3 months before and ≥6 months after the index date
N=67,912

No ADA claim before index datec (ADA‐naïve patients)
N=37,930

≥1 diagnosis for an autoimmune disease of interest before the index dated
N=30,817

≥18 years of age at index date
N=29,999

Opted into any component of the PSP
N=22,479

Participated in
Ambassador program
PSP cohort: N=9851

Did not opt into PSP
Non‐PSP cohort: N=7520

IBD
N=4046

IBD
N=2446

RA
N=2475

RA
N=2254

PsO
N=1844

PsO
N=1412

PsA
N=813

PsA
N=750

AS
N=246

AS
N=304

HS
N=314

HS
N=217

UV
N=113

UV
N=137

Figure 1 Study sample selection.
Notes: aDirect feed claims consisted of ﬁlled claims only and were excluded from abandonment analysis. The following treatments were included: etanercept, inﬂiximab, certolizumab,
golimumab, anakinra, tocilizumab, secukinumab, ixekizumab, ustekinumab, abatacept, rituximab, natalizumab, vedolizumab, tofacitinib, and apremilast. bClaims with governmentprovided insurance were excluded as these patients were prohibited from using all components of the PSP. cDetermined using all available claims from 1/1/2006 to the index date.
d
Autoimmune diseases included rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and uveitis.
Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; HS, hidradenitis suppurativa; IBD, inﬂammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis; PSP,
patient support program; RA, rheumatoid arthritis; UV, uveitis.
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of the initial ADA claim as the dependent variable, controlling for age, sex, household income, year, copayment
amount, plan type, pharmacy type, indication, and comorbidity burden. Results were further stratiﬁed by primary
indication so that each comparison was conducted on a
unique sample. Separate models were run for each indication and odds ratios (ORs) and 95% conﬁdence intervals
(CIs) were reported overall and for each indication. In all
analyses, a two-sided alpha error level of 0.05 was used to
indicate statistical signiﬁcance. A sensitivity analysis measuring PSP enrollment strictly prior to the initial ADA
claim was performed. All analyses were conducted using
SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).

Results
A total of 17,371 patients (9851 in the PSP cohort and
7520 in the non-PSP cohort) were included in the analysis
(Figure 1). Of the 17,371 patients in the study population,
6492 (37.4%) had inﬂammatory bowel disease, 4729
(27.2%) had rheumatoid arthritis, 3256 (18.7%) had psoriasis, 1563 (9.0%) had psoriatic arthritis, 550 (3.2%) had
ankylosing spondylitis, 531 (3.1%) had hidradenitis suppurativa, and 250 (1.4%) had uveitis. Analysis of the baseline characteristics of the study population revealed a few
signiﬁcant differences between the two cohorts. Compared
with the non-PSP cohort, the PSP cohort was younger
(mean age 45.6 vs 46.4 years; P<0.001), and had a lower
comorbidity score39 (mean Charlson Comorbidity Index:
0.38 vs 0.47; P<0.001, Table 1). Also, the expected perpatient out-of-pocket contribution for ADA was 45.1%
lower ($344 vs $627; P<0.001) and the frequency of
specialty pharmacy use for the ﬁrst ADA prescription ﬁll
was 44.3% greater (75.6% vs 52.4%; P<0.001) in the PSP
cohort compared with the non-PSP cohort.
Overall, abandonment of ADA initiation was 12.0% and
was consistent across calendar years (11.7% in 2015 and
12.7% in 2016) and indications (range: 10.8% for uveitis to
16.8% for hidradenitis suppurativa). As shown in Figure 2,
the overall abandonment rate across all indications was
reduced by 73% for the PSP cohort compared with the
non-PSP cohort (5.6% vs 20.4%, respectively, P<0.001).
Separate models were run for each indication and showed
signiﬁcant reductions in abandonment rates for each indication: 72% (5.9% vs 21.1%) for inﬂammatory bowel disease,
73% (5.2% vs 19.3%) for rheumatoid arthritis, 76% (5.3%
vs 22.1%) for psoriasis, 71% (5.2% vs 17.7%) for psoriatic
arthritis, 73% (5.3% vs 19.7%) for ankylosing spondylitis,
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67% (9.2% vs 27.6%) for hidradenitis suppurativa, and 79%
(3.5% vs 16.8%) for uveitis; all P<0.001.
After controlling for potentially confounding baseline
characteristics (ie, age, sex, household income, expected
patient copayment, calendar year of index date, type of
insurance plan, type of pharmacy used, indication, and
comorbidity burden), the odds of abandonment overall
were 70% lower for the PSP cohort compared with the
non-PSP cohort (OR =0.30, 95% CI=0.27–0.33, P<0.001;
Table 2). Adjusted abandonment rates for each indication
were signiﬁcantly (all P≤0.01) lower in the PSP cohort
than in the non-PSP cohort: 72% lower (OR =0.28, 95%
CI=0.24–0.34) for inﬂammatory bowel disease, 66% (OR
=0.34, 95% CI=0.27–0.42) for rheumatoid arthritis, 73%
(OR =0.27, 95% CI=0.20–0.35) for psoriasis, 66% (OR
=0.34, 95% CI=0.22–0.52) for psoriatic arthritis, 76% (OR
=0.24, 95% CI=0.11–0.50) for ankylosing spondylitis,
75% (OR =0.25, 95% CI=0.14–0.45) for hidradenitis suppurativa, and 82% (OR =0.18, 95% CI=0.05–0.67) for
uveitis (Table 3). Results of a sensitivity analysis measuring PSP enrollment strictly prior to the initial ADA claim
were similar to those reported in the main analysis.
Among patients who successfully initiated ADA treatment (n=15,281), the odds of a subsequent ADA ﬁll after
the ﬁrst prescription ﬁll were 36% higher for the PSP
cohort compared with the non-PSP cohort (87.0% vs
82.8%; OR =1.36, 95% CI=1.23–1.51, P<0.001).
The odds of ADA prescription abandonment were 38%
lower for patients obtaining their prescription from a specialty pharmacy than from a retail pharmacy (OR =0.62,
95% CI=0.56–0.69, P<0.001; Table 2), 20% lower among
patients with a household income of $50–$99K than those
with an income of $0–$49K (OR =0.80, 95% CI=0.69–
0.92, P<0.01), and 78% greater among patients with a
copayment of $26–$100 compared with a copayment of
$0–$25 (OR =1.78, 95% CI=1.55–2.05; P<0.001).

Discussion
Abandonment of prescribed drug treatment has important
implications for patient-centered health outcomes. Patients
who abandon their initial prescription for drug therapy
ultimately delay treatment initiation or forego treatment
altogether. Abandoning or delaying treatment initiation
could have serious consequences and result in poor clinical
outcomes and increased health care costs to payers.
Reasons that patients abandon prescribed treatment may
include the cost burden of therapy, misconceptions about
the illness, or perceived beneﬁts of treatment.38,40–43
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Table 1 Baseline characteristics of the study population
Characteristic

PSP N=9851

Non-PSP N=7520

P-valuea

Age (years), mean ± SD

45.6±13.3

46.4±13.9

<0.001

Male, n (%)

3817 (38.7)

2935 (39.0)

0.71

$0–$49,999

1694 (17.2)

1486 (19.8)

<0.001

$50,000–$99,999

2778 (28.2)

2106 (28.0)

0.78

>$100,000
Unknown

2402 (24.4)
2977 (30.2)

1480 (19.7)
2448 (32.6)

<0.001
<0.001

$344±$1601
7685 (78.0)

$627±$2042
4183 (55.6)

<0.001
<0.001

$26–$100, n (%)

902 (9.2)

1581 (21.0)

<0.001

$101–$500, n (%)
$501–$1000, n (%)

437 (4.4)
150 (1.5)

586 (7.8)
225 (3.0)

<0.001
<0.001

$1001–$2000, n (%)

160 (1.6)

195 (2.6)

<0.001

>$2000, n (%)

517 (5.2)

750 (10.0)

<0.001

2015

6152 (62.5)

5146 (68.4)

<0.001

2016

3699 (37.5)

2374 (31.6)

<0.001

Commercial
Employer group

3794 (38.5)
584 (5.9)

475 (6.3)
703 (9.3)

<0.001
<0.001

Third party administrator

27 (0.3)

47 (0.6)

<0.001

Pharmacy beneﬁt manager
Cash

1887 (19.2)
180 (1.8)

2432 (32.3)
361 (4.8)

<0.001
<0.001

Household income, n (%)

Expected patient copay, mean ± SD
$0–$25, n (%)

Calendar year, n (%)

Primary plan, n (%)

Processors

41 (0.4)

71 (0.9)

<0.001

Unspeciﬁed or missing

3338 (33.9)

3431 (45.6)

<0.001

Initial claim at specialty pharmacy, n (%)b

7443 (75.6)

3938 (52.4)

<0.001

Charlson Comorbidity Index, mean ± SD

0.38±0.70

0.47±0.84

<0.001

Indications, n (%)
Inﬂammatory bowel disease

4046 (41.1)

2446 (32.5)

<0.001

Rheumatoid arthritis

2475 (25.1)

2254 (30.0)

<0.001

Psoriasis
Psoriatic arthritis

1844 (18.7)
813 (8.3)

1412 (18.8)
750 (10.0)

0.92
<0.001

Ankylosing spondylitis

246 (2.5)

304 (4.0)

<0.001

Hidradenitis suppurativa
Uveitis

314 (3.2)
113 (1.1)

217 (2.9)
137 (1.8)

0.25
<0.001

Notes: aWilcoxon rank-sum tests and chi-square tests were used to compare continuous and categorical variables, respectively. bDeﬁned as a pharmacy type of mail order/
specialty.
Abbreviations: PSP, patient support program; SD, standard deviation.

Because lack of motivation or knowledge regarding treatment can also inﬂuence whether patients initiate therapy,44
we assessed the effect of AbbVie’s PSP on the odds of
ADA abandonment among patients with various autoimmune disorders. While all PSP patients included in the
study participated in the Ambassador program, which
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provides face-to-face interactions to motivate and support
patients to manage their treatment regimen and care as
prescribed, they may have also utilized other PSP components such as insurance and ﬁnancial assistance education,
refresher injection training to supplement the initial training provided by the physician and resources to familiarize
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PSP Cohort

Non‐PSP Cohort

67% reduction

30
27.6
76% reduction

25

73% reduction

72% reduction
73% reduction

Abandonment Rate, %

73% reduction

22.1

21.1

20.4

71% reduction

79% reduction

19.7

19.3

20

17.7

16.8

15

9.2*

10
5.9*

5.6*

5.3*

5.2*

5.3*

5.2*

5

0

3.5*

n=9851

n=7520

All Patients

n=4046

n=2446

IBD

n=2475

n=2254

RA

n=1844

n=1412

PsO

n=813

n=750

PsA

n=246

n=304

AS

n=217

n=314

HS

n=113

n=137

UV

Figure 2 Prevalence of abandonment by PSP participation for the overall study population and individual indications.
Notes: Relative percent change = (PSP–Non-PSP)/Non-PSP. Asterisk (*) indicates the comparison of PSP versus non-PSP cohorts was statistically signiﬁcant (P<0.001). Pvalue was based on 2-sample z-test of proportions.
Abbreviations: AS, ankylosing spondylitis; HS, hidradenitis suppurativa; IBD, inﬂammatory bowel disease; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; UV, uveitis.

patients with the self-injection process, as well as ongoing
treatment-related resources (including pen and sharp disposal), and medication reminders. In the overall population, the abandonment rate was 70% lower in the PSP
cohort than in the non-PSP cohort. Similar reductions in
abandonment rates were observed when each indication
was analyzed separately. These ﬁndings suggest that medication cost assistance as well as motivating and supporting patients prior to treatment initiation may reduce the
odds of prescription abandonment and are not necessarily
dependent on the disease characteristics in question. The
PSP provides education and copayment assistance, and
both are expected to impact prescription abandonment.
The PSP also provides services such as injection training
and reﬁll reminders, which are expected to impact secondary adherence. Subsequent ADA prescription reﬁll is a
measure of the latter, and results from our study indicate
that among patients who successfully initiated ADA, the
odds of a subsequent ADA reﬁll after the ﬁrst prescription
ﬁll was 36% higher among patients participating in the
PSP program. While this could be an indication that components of the PSP, such as injection training and education, increased the likelihood of continuing treatment, the
contribution of speciﬁc components was not examined in
this study and continuation beyond a second ﬁll was not
evaluated, both of which could be topics of further
research.
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In our study, the overall treatment abandonment rate
was 12%, which is less than the abandonment rate of
38.6% reported in the study of Harnett et al (2016).25
There are some differences between Harnett et al (2016)
and our study that may explain the lower abandonment
rate we observed. Harnett et al (2016) used electronic
health records as the data source and the analysis assessed
all written prescriptions including those that patients may
not have taken to the pharmacy to ﬁll as well as prescription claims that were denied by the insurer.25 In contrast,
we used a claims database and assessed abandonment as
prescriptions that were approved by the insurer and ﬁlled
by the pharmacy, but not picked up by the patient.
A few studies have reported a strong association of higher
cost sharing with abandonment of specialty drug prescriptions for various indications, including multiple sclerosis,
rheumatoid arthritis, and cancer.37,38,43 Results of our multivariable analysis also indicate that the odds of prescription
abandonment increase as the patient’s copayment increases.
In the current study, the mean patient copayment was $344
and $627 for the PSP and non-PSP cohorts, respectively.
These mean copays are near the costs expected to substantially increase abandonment rates.37,38,43 Other factors that
may inﬂuence prescription abandonment include fear of side
effects associated with starting a new medication, fear of selfinjecting the medication, or a lack of understanding of the
long-term beneﬁts of therapy. Engaging patients to become
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Table 2 Multivariable analysis of the odds of abandonment of
treatment with ADA
Characteristic

All indications
Odds ratio

P-value

(95% CI)
Opt-in to PSPa

0.30 (0.27–0.33)

<0.001

Age (years)

1.01 (1.01–1.01)

<0.001

Male

0.92 (0.83–1.02)

0.12

$0–$49,999
$50,000–$99,999

Ref
0.80 (0.69–0.92)

—
<0.01

≥$100,000

0.76 (0.65–0.90)

<0.001

Unknown

0.87 (0.75–1.00)

<0.05

Household income

Expected patient copay
$0–$25

Ref

—

$26–$100

1.78 (1.55–2.05)

<0.001

$101–$500
$501–$1000

2.56 (2.13–3.08)
5.08 (3.98–6.49)

<0.001
<0.001

$1001–$2000
>$2000

8.28 (6.52–10.52)
9.75 (8.27–11.49)

<0.001
<0.001

2015

0.89 (0.80–0.99)

0.04

2016

Ref

—

Calendar year

Primary plan
Commercial

Ref

—

Employer group

1.47 (1.18–1.83)

<0.001

Third party administrator
Pharmacy beneﬁt manager

1.12 (0.56–2.24)
1.09 (0.91–1.31)

0.74
0.35

Cash

0.87 (0.66–1.15)

0.33

Processors
Unspeciﬁed or missing

1.70 (1.07–2.70)
1.14 (0.96–1.36)

0.02
0.12

Initial claim at specialty pharmacy

0.62 (0.56–0.69)

<0.001

Charlson Comorbidty Index

1.01 (0.95–1.08)

0.74

Rheumatoid arthritis
Inﬂammatory bowel disease

Ref
1.37 (1.19–1.58)

—
<0.001

Psoriasis

1.30 (1.11–1.53)

<0.001

Psoriatic arthritis
Ankylosing spondylitis

0.99 (0.81–1.22)
1.18 (0.88–1.58)

0.95
0.26

Hidradenitis suppurativa

1.98 (1.50–2.61)

<0.001

Uveitis

0.92 (0.59–1.43)

0.71

Indications

a

Note: Non-PSP cohort was the reference.
Abbreviations: ADA, adalimumab; CI, conﬁdence interval; PSP, patient support
program; Ref, reference.

partners in their own treatment and providing educational
information regarding setting long-term therapy goals with
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their physician and addressing quality-of-life issues may
reduce the effect of these other factors. For patients with
chronic disease (eg, rheumatoid arthritis, multiple sclerosis,
diabetes), positive beneﬁts in terms of increased medication
adherence and improved quality of life have been demonstrated through medication-focused PSPs.30–34,45 PSPs
accomplish these goals by helping patients self-manage
their condition by providing individualized medication counseling, training, and educational materials.34 Indeed, results
from our study indicate that engaging patients through the
PSP not only reduces initial ADA prescription abandonment
but also increases the odds that a second ADA prescription
will be ﬁlled.
Though our study did not examine long-term outcomes, the reﬁll likelihood results are consistent with
prior studies demonstrating that providing patient support
positively inﬂuences patient behavior throughout the ﬁrst
year of treatment. A recent study showed that over a 12month period, ADA adherence was 14% greater in patients
participating in AbbVie’s PSP and the discontinuation rate
for ADA was 14% lower among patients participating in
AbbVie’s PSP compared with those who were not
participants.36 In addition, 12-month medical costs
(excluding biologic treatment costs) and disease-related
medical costs were 23% and 22% lower, respectively, for
PSP patients than non-PSP patients.36 As the AbbVie PSP
has evolved over time, additional research has shown
consistent results regarding adherence and medical costs
and demonstrated the continued value of the PSP for
ADA-treated patients.46 A separate study47 showed that
providing educational information and encouraging
patients to adhere to a newly prescribed statin resulted in
greater dispensation of the statin prescription in the intervention group compared with controls (42.3% vs 26.0%).
Both studies demonstrate the importance of interacting
with patients to improve adherence to a treatment regimen
and ultimately improve quality of care for patients.
This is the ﬁrst study to assess the relationship between
participation in a comprehensive PSP and ADA abandonment rates across autoimmune diseases in the US. One of
the strengths of this analysis is that the claims data provide
results for a large, commercial patient population that
includes multiple indications treated with ADA. Another
strength of this study is that we could examine the temporal relationship between opting into the PSP and ADA
treatment abandonment because the database contains
longitudinal, patient-level information on medical and
pharmacy claims. Finally, unlike the data obtained in
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0.78 (0.65–0.92)**

Male
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1.03 (0.80–1.32)

0.78 (0.60–1.03)
0.92 (0.72–1.18)

$50,000–$99,999

≥$100,000
Unknown

5.03 (3.10–8.17)***
10.27 (7.95–13.27)***

$501–$1000

$1001–$2000
>$2000
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1.33 (0.91–1.92)
1.33 (0.38–4.65)

1.05 (0.77–1.42)

0.53 (0.32–0.87)*
1.77 (0.92–3.40)

1.20 (0.90–1.59)

0.57 (0.48–0.68)***
0.96 (0.84–1.10)

Employer group
TPA

PBM

Cash
Processors

Unspeciﬁed or missing

Initial claim at SP
CCI

0.64 (0.53–0.79)***
1.04 (0.93–1.16)

1.20 (0.87–1.67)

0.81 (0.47–1.39)
1.91 (0.62–5.87)

1.17 (0.83–1.66)

1.33 (0.88–2.00)
1.26 (0.37–4.31)

Ref

0.90 (0.73–1.11)
Ref

11.72 (7.78–17.65)***
9.60 (6.77–13.61)***

6.15 (4.11–9.20)***

1.74 (1.32–2.31)***
2.92 (2.03–4.21)***

Ref

0.65 (0.48–0.89)**
0.75 (0.58–0.98)*

0.66 (0.51–0.86)**

Ref

1.03 (0.82–1.31)

1.01 (1.00–1.02)*

0.73 (0.57–0.93)*
0.92 (0.76–1.12)

1.10 (0.74–1.63)

1.08 (0.57–2.03)
1.56 (0.38–6.39)

0.95 (0.62–1.46)

1.60 (0.95–2.68)
0.58 (0.11–3.16)

Ref

0.87 (0.68–1.10)
Ref

8.13 (4.89–13.50)***
9.62 (6.59–14.05)***

4.19 (2.39–7.36)***

2.01 (1.46–2.75)***
3.10 (2.11–4.55)***

Ref

0.92 (0.64–1.31)
0.99 (0.71–1.38)

0.73 (0.52–1.03)

Ref

1.14 (0.90–1.43)

1.01 (1.00–1.02)

0.27 (0.20–0.35)***

OR (95% CI)

PsO

0.57 (0.39–0.82)**
1.08 (0.88–1.32)

1.51 (0.79–2.92)

2.98 (1.13–7.90)*
2.14 (0.48–9.46)

1.16 (0.57–2.36)

2.30 (1.01–5.25)*
3.10 (0.24–39.60)

Ref

1.15 (0.75–1.76)
Ref

13.34 (6.27–28.40)***
13.00 (7.37–22.94)***

7.48 (3.09–18.11)***

1.33 (0.77–2.30)
3.16 (1.69–5.91)***

Ref

0.85 (0.49–1.47)
0.94 (0.55–1.61)

0.57 (0.33–0.98)*

Ref

0.93 (0.64–1.35)

1.02 (1.00–1.04)*

0.34 (0.22–0.52)***

OR (95% CI)

PsA

0.35 (0.19–0.64)***
1.02 (0.74–1.40)

0.52 (0.19–1.41)

2.52 (0.60–10.48)
0.62 (0.03–12.08)

1.32 (0.51–3.44)

1.90 (0.58–6.27)
—

Ref

0.69 (0.37–1.28)
Ref

4.16 (0.76–22.75)
4.85 (1.59–14.79)**

6.23 (1.75–22.14)**

1.07 (0.46–2.49)
4.09 (1.37–12.17)*

Ref

0.49 (0.20–1.21)
0.48 (0.20–1.16)

1.24 (0.57–2.71)

Ref

0.57 (0.32–1.01)

1.02 (0.99–1.04)

0.24 (0.11–0.50)***

OR (95% CI)

AS

0.51 (0.29–0.89)*
1.16 (0.84–1.59)

0.46 (0.20–1.07)

0.33 (0.07–1.66)
0.54 (0.08–3.72)

0.57 (0.24–1.38)

1.01 (0.36–2.90)
0.93 (0.06–15.01)

Ref

1.15 (0.68–1.96)
Ref

11.78 (1.79–77.50)*
11.98 (5.31–27.00)*

2.61 (0.29–23.37)

2.39 (1.20–4.78)*
2.63 (1.06–6.55)*

Ref

0.88 (0.33–2.32)
0.99 (0.50–1.97)

0.72 (0.35–1.49)

Ref

0.92 (0.51–1.67)

1.01 (0.99–1.04)

0.25 (0.14–0.45)***

OR (95% CI)

HS

1.77 (0.61–5.17)
0.73 (0.30–1.79)

1.67 (0.22–12.58)

4.36 (0.16–120.84)
—

7.40 (1.02–53.63)*

7.14 (0.74–68.95)
—

Ref

1.20 (0.43–3.35)
Ref

2.18 (0.12–38.78)
4.68 (0.39–55.75)

55.52 (2.40–999.99)*

1.24 (0.37–4.17)
10.85 (2.22–53.04)**

Ref

1.30 (0.21–7.91)
3.04 (0.58–15.94)

1.80 (0.32–10.17)

Ref

2.58 (0.89–7.50)

1.05 (1.01–1.10)*

0.18 (0.05–0.67)*

OR (95% CI)

UV

Notes: aNon-PSP cohort was the reference. *P<0.05, ** P<0.01, *** P<0.001.
Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; CCI, Charlson Comorbidity Index; CI, conﬁdence interval; HS, hidradenitis suppurativa; IBD, inﬂammatory bowel disease; OR, odds ratio; PBM, pharmacy beneﬁt manager;
PsA, psoriatic arthritis; PsO, psoriasis; PSP, patient support program; RA, rheumatoid arthritis; Ref, reference; SP, specialty pharmacy; TPA, third party administrator; UV, uveitis.

Ref

Commercial

Primary plan

2015
2016

0.83 (0.70–0.99)*
Ref

3.90 (2.41–6.30)***

$26–$100
$101–$500

Calendar year

Ref

1.82 (1.45–2.28)***
1.79 (1.28–2.49)***

$0–$25

Expected patient copay

Ref

$0–$49,999

Household income

1.01 (1.00–1.02)**

0.34 (0.27–0.42)***

OR (95% CI)

OR (95% CI)

0.28 (0.24–0.34)***

RA

IBD

Age (years)

Opt-in to PSP

a

Characteristic

Table 3 Multivariable analysis of the odds of abandonment of treatment with ADA by indication
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highly controlled clinical trials, the claims data accurately
reﬂect real-world patterns of nonadherence.

Limitations
There are some limitations to this analysis that should be noted.
First, because this was an observational study and not a randomized controlled clinical trial, any unobservable factors in data
may not be balanced between the study groups. For example,
sociodemographic disparities in access to prescribed treatment
and enrollment in the support program could not be comprehensively evaluated because these data were not available in
the source data, but they should be a topic of future research.
Though we have controlled for an extensive list of observable
characteristics, because of the potential for unobservable heterogeneity, results should be interpreted as the association
between PSP participation and prescription abandonment, not
necessarily a causal effect. As with all observational studies,
there is a possibility of selection bias as patients who chose to
opt-in to the PSP may have unique characteristics that affect
the probability of initiating therapy. Second, opting-in to the
PSP may occur after the initial claim during the period when
abandonment is assessed; however, a sensitivity analysis
which focused on patients who opted-in to the PSP prior to
the initial claim had similar ﬁndings. Third, non-electronic
prescriptions abandoned prior to submission to a pharmacy
are not observed in the data, which may result in underestimating the true abandonment rate. Fourth, many patients ﬁrst
present a copay card at the time of ﬁll, and thus the data may
not capture copay cards for patients who abandon their script
without appearing at the pharmacy. As such, the expected
copay for these patients may be overestimated. Fifth, the contributions of speciﬁc components and the beneﬁts of increased
use of the PSP were not estimated and analysis of patients who
were excluded (eg, those who received government-provided
insurance) are areas of continued research. Sixth, the study
only considered prescription ﬁlls to 6 months following the
initial ADA claim, so conclusions cannot be made about longterm treatment patterns or consequences of abandonment.
Finally, an enrollment or eligibility ﬁle was not available for
the SHS data, so a subsequent pharmacy claim was required to
ensure a continuous period of data coverage, which may have
affected the observed abandonment rate.

Conclusions
Abandonment of ADA initiation is a signiﬁcant problem
potentially affecting patient outcomes across autoimmune
indications. This study demonstrated that participation in
AbbVie’s PSP was associated with substantially lower
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abandonment of the ﬁrst prescription and increased odds
of subsequent prescription ﬁlls by engaging and supporting patients before treatment initiation. Future studies are
needed to assess whether reducing treatment abandonment
through the PSP leads to better clinical outcomes and
helps to control health care costs in patients with chronic
inﬂammatory diseases requiring long-term care.
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